

Biosimulation Technology: Market Research Report

https://marketpublishers.com/r/B5020DD2662EN.html Date: January 2015 Pages: 164 Price: US\$ 4,500.00 (Single User License) ID: B5020DD2662EN

Abstracts

This report analyzes the worldwide markets for Biosimulation Technology in US\$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as -

Advanced Chemistry Development, Inc.

Biovia

Certara L.P

Chemical Computing Group

Entelos, Inc.



Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting Level Quantitative Techniques & Analytics Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Biosimulation: Massively Benefiting Drug R&D Current and Future Analysis Application and End-user Areas

Table 1. Global Biosimulation Market by Application (2014): Percentage Share of Revenue in Drug Development, Drug Discovery, and Others (includes corresponding Graph/Chart)

Table 2. Global Biosimulation Market by End-user Sector (2014): Percentage Share of Revenue for Academic Research Institutes, Biotechnology/Drug Companies, Contract Research Organizations (CROs), Regulatory Organizations, and Others (includes corresponding Graph/Chart)

Biosimulation Offers Paradigm Shift in Drug Development Key Market Drivers in a Nutshell Market Restraints Competition

2. GROWTH DRIVERS

Increasing Healthcare Expenditure Drives the Need for Drug Discovery and Development



Table 3. Per Capita Healthcare Expenditure in US\$ by Select Country (includes corresponding Graph/Chart)

Table 4. Healthcare Expenditure as % of GDP by Select Country (includescorresponding Graph/Chart)

Increasing Incidence and Prevalence of CDDs: A Major Growth Driver

Table 5. Worldwide Incidence of Cancer in Million: 2012, 2020 & 2030 (includescorresponding Graph/Chart)

Table 6. Global Annual Medical Cost of CVD in US\$ Billion (2010-2030) (includescorresponding Graph/Chart)

Aging Global Population Drives Advanced Drug R&D

Table 7. Global Population Statistics for the 65+ Age Group (2012) (includescorresponding Graph/Chart)

Table 8. Elderly Population (65+ Years) as a % of Total Population (2000 & 2025)(includes corresponding Graph/Chart)

High Costs Associated with Traditional Drug Discovery

Table 9. Escalating Costs of New Drug Development Over the Decades (includescorresponding Graph/Chart)

Table 10. US R&D Productivity Trends in Pharma Industry (2006- 2013) (includescorresponding Graph/Chart)

High Failure Rate of Late-Stage Drug Trials List of Recent Late-stage Drug Failures (2014) China and India: Hot Spots for R&D Investment

Table 11. Percentage Breakup of Global R&D Spending by Region (2012) (includes



corresponding Graph/Chart)

Biosimulation Overcomes Challenges in Pediatric Drug Development

3. MARKET TRENDS – AN INSIGHT

Simulation Tools Take the Pressure off Mounting Life Science R&D Budgets

Table 12. Global Life Science R&D Expenditure (2011-2014): Total R&D Spending inUS\$ Billion (includes corresponding Graph/Chart)

Biosimulation Gets Neurodegenerative Disease Out of the Cul-de-sac Marking New Avenues in Diabetes Research Biosimulation Moving From Discovery Aid to Clinical Tool Lung Biosimulation: Game Changer for OIP Development Biosimulation for Drug Repositioning Grid-based Docking Aids Biosimulation Need for Better Models: A Major Factor Driving Innovation in the Market

4. TECHNOLOGY OVERVIEW

Biosimulation - A Brief Introduction Drug Discovery and Development Stages in Drug Development Process Target identification Target Validation Lead Identification Lead Optimization Pre-Clinical Testing Clinical Trials Drug Discovery Technologies Human Physiology Mathematical Models and Biosimulation Technique Bottom-up Modeling Top-Down Modeling

5. PRODUCT LAUNCHES/APPROVALS



Certara Launches Simcyp In Vitro Analysis Toolkit Version 1. Optimata Granted US Patent for Biosimulation Technology Cognigen Releases Version 1. 3 of KIWI Simulations Plus Releases Version 9. 0 of GastroPlus Certara Launches Version 2. 0 of Cardiac Safety Simulator Certara Releases Version 14 of Simcyp Simulator Certara Receives FDA Grant for MechDermA Physiomics Launches EasyAP Rhenovia Pharma Develops Simulator for Epilepsy Mechanisms Insilico Biotechnology Launches Simulation Platform for Virtual Organs

6. RECENT INDUSTRY ACTIVITY

Certara Merges Its Pharsight Consulting with Quantitative Solutions Optivia Biotechnology and Rhenovia Pharma Sign Partnership Agreement Physiomics Signs Contract with Merck Serono PMDA Equips Pharmacometrics Team with Certara's Biosimulation Solutions CQDM and Alsace-Biovalley Collaborate on Biosimulation Platform Dassault Systèmes Acquires Accelrys Rhenovia Pharma Secures Series B Funding Pharmacelsus and Insilico Biotechnology Collaborate for Preclinical Drug Analysis Arsenal Capital Partners Acquires Certara Entelos Enters Into Licensing Agreement with USFDA

7. FOCUS ON SELECT GLOBAL PLAYERS

Advanced Chemistry Development, Inc. (Canada) Biovia (Formerly Accelrys) (US) Certara L. P. (US) Chemical Computing Group (Canada) Entelos, Inc. (US) In Silico Biosciences, Inc. (US) InhibOx (UK) Insilico Biotechnology AG (Germany) LeadInvent Technologies (India) Leadscope, Inc. (US) Nimbus Therapeutics (US) OpenEye Scientific Software Inc. (US) Physiomics Plc. (UK)



Rhenovia Pharma SAS (France) Schrodinger, LLC (US) Simulations Plus, Inc. (US)

8. GLOBAL MARKET PERSPECTIVE

Table 13. World Recent Past, Current & Future Analysis for Biosimulation Technologyby Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, andRest of World Markets Independently Analyzed with Annual Sales Figures in US\$Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 14. World 8-Year Perspective for Biosimulation Technology by GeographicRegion - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2013, 2015 & 2020(includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis Biosimulation to Abate Life Sciences R&D Spending

Table 15. The US Life Science Industry Annual R&D Expenditure: 2011-2014 (includescorresponding Graph/Chart)

Ageing Population – Booster for Effective Drug Development

Table 16. North American Elderly Population by Age Group: 1975-2050 (includescorresponding Graph/Chart)

Rise in Chronic Disorders Drive Market Growth

Table 17. US Diabetics Population (2010-2017): Percentage Population with Diagnosed

 and Undiagnosed Diabetes (includes corresponding Graph/Chart)



Table 18. High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Age Groups (includes corresponding Graph/Chart)

Table 19. High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male

 and Female Population by Ethnic Group (includes corresponding Graph/Chart)

Table 20. New Cancer Cases in the US by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)

Product Launches Strategic Corporate Developments Key Players B. Market Analytics

Table 21. The US Recent Past, Current & Future Analysis for Biosimulation TechnologyAnalyzed with Annual Sales Figures in US\$ Thousand for Years 2013 through 2020(includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis Increasing Incidence of Cancer: A Major Growth Driver

Table 22. New Cancer Cases in Canada by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)

Strategic Corporate Development Key Players B. Market Analytics

Table 23. Canadian Recent Past, Current & Future Analysis for BiosimulationTechnology Analyzed with Annual Sales Figures in US\$ Thousand for Years 2013through 2020 (includes corresponding Graph/Chart)

3. JAPAN



A. Market Analysis Graying Population Spurs Demand for Advanced Drug Development

 Table 24. Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)

Strategic Corporate Development B. Market Analytics

Table 25. Japanese Recent Past, Current & Future Analysis for BiosimulationTechnology Analyzed with Annual Sales Figures in US\$ Thousand for Years 2013through 2020 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis Regulatory Authorities Stress on Paradigm Shift in Drug Development Ageing Population Boosts Demand

Table 26. European Country-wise Statistics of 60+ Population as % of Total Population:2013 (includes corresponding Graph/Chart)

B. Market Analytics

Table 27. European Recent Past, Current & Future Analysis for BiosimulationTechnology by Geographic Region - France, Germany, Italy, UK, Spain, Russia, andRest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 28. European 8-Year Perspective for Biosimulation Technology by GeographicRegion - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain,Russia, and Rest of Europe Markets for Years 2013, 2015 & 2020 (includescorresponding Graph/Chart)

4A. FRANCE



A. Market Analysis
Strategic Corporate Developments
Rhenovia Pharma SAS – A Key Player
B. Market Analytics

Table 29. French Recent Past, Current & Future Analysis for Biosimulation TechnologyAnalyzed with Annual Sales Figures in US\$ Thousand for Years 2013 through 2020(includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Product Launch
Strategic Corporate Development
Insilico Biotechnology AG – A Key Player
B. Market Analytics

Table 30. German Recent Past, Current & Future Analysis for BiosimulationTechnology Analyzed with Annual Sales Figures in US\$ Thousand for Years 2013through 2020 (includes corresponding Graph/Chart)

4C. ITALY

Market Analysis

Table 31. Italian Recent Past, Current & Future Analysis for Biosimulation TechnologyAnalyzed with Annual Sales Figures in US\$ Thousand for Years 2013 through 2020(includes corresponding Graph/Chart)

4D. UNITED KINGDOM

A. Market AnalysisProduct LaunchStrategic Corporate DevelopmentKey Players



B. Market Analytics

Table 32. The UK Recent Past, Current & Future Analysis for Biosimulation TechnologyAnalyzed with Annual Sales Figures in US\$ Thousand for Years 2013 through 2020(includes corresponding Graph/Chart)

4E. SPAIN

Market Analysis

Table 33. Spanish Recent Past, Current & Future Analysis for BiosimulationTechnology Analyzed with Annual Sales Figures in US\$ Thousand for Years 2013through 2020 (includes corresponding Graph/Chart)

4F. RUSSIA

Market Analysis

Table 34. Russian Recent Past, Current & Future Analysis for BiosimulationTechnology Analyzed with Annual Sales Figures in US\$ Thousand for Years 2013through 2020 (includes corresponding Graph/Chart)

4G. REST OF EUROPE

Market Analysis

Table 35. Rest of European Recent Past, Current & Future Analysis for BiosimulationTechnology Analyzed with Annual Sales Figures in US\$ Thousand for Years 2013through 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis Growing Population and Aging Demographic Drive Demand for Advanced Drug Development



Table 36. Population Statistics in Asia (Including Japan) & Percentage of PopulationAged Above 65 Years (includes corresponding Graph/Chart)

Leadinvent Technologies (India) – A Key Player B. Market Analytics

Table 37. Asia-Pacific Recent Past, Current & Future Analysis for BiosimulationTechnology Analyzed with Annual Sales Figures in US\$ Thousand for Years 2013through 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA

Market Analysis

Table 38. Latin American Recent Past, Current & Future Analysis for BiosimulationTechnology Analyzed with Annual Sales Figures in US\$ Thousand for Years 2013through 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

A. Market AnalysisProduct LaunchB. Market Analytics

Table 39. Rest of World Recent Past, Current & Future Analysis for BiosimulationTechnology Analyzed with Annual Sales Figures in US\$ Thousand for Years 2013through 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 42 (including Divisions/Subsidiaries - 44) The United States (18) Canada (2) Japan (2)



Europe (19) France (2) Germany (4) The United Kingdom (6) Spain (1) Rest of Europe (6) Asia-Pacific (Excluding Japan) (1) Middle East (2)



I would like to order

Product name: Biosimulation Technology: Market Research Report Product link: https://marketpublishers.com/r/B5020DD2662EN.html Price: US\$ 4,500.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/B5020DD2662EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970